Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy


Pracinostat, an emerging hydroxamate histone deacetylase (HDAC) inhibitor has shown better efficacy than approved inhibitor suberoylanilide hydroxamic acid (SAHA). Apart from haematological malignancies, this inhibitor has shown promising results in preclinical models of solid tumours. Being pan-inhibitor pracinostat targets various classical HDACs and has demonstrated antiproliferative properties in a series of cancer cell lines. Currently, no energetic and structural studies are available about the pracinostat against four HDAC isozymes of Class I. Taking this into account, the current study involved flexible molecular docking for gaining insights regarding pracinostat-HDAC isozyme interactions, molecular mechanics generalized born surface area (MM-GBSA) for estimating binding affinity of this inhibitor towards these isozymes and energetically optimized pharmacophores (e-Pharmacophores) technique for delineating the critical e-pharmacophoric features of pracinostat in its least energy state in the binding pocket of these HDACs. The outcome from this study will help in further optimization of pracinostat towards better therapeutic and the e-Pharmacophores generated will serve as queries in e-Pharamcophores guided virtual screening.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. Balaji B, Ramanathan M (2012) Prediction of estrogen receptor β ligands potency and selectivity by docking and MM-GBSA scoring methods using three different scaffolds. J Enzyme Inhib Med Chem 27:832–844

    CAS  Article  Google Scholar 

  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE, 2000. The Protein Data Bank. Nucleic acids research 28, 235–242

  3. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL, Golub TR, Ebert BL (2010a) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A 107:12617–12622

    CAS  Article  Google Scholar 

  4. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R (2010b) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238–243

    CAS  Article  Google Scholar 

  5. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med chem 47:1739–1749

    CAS  Article  Google Scholar 

  6. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196

    CAS  Article  Google Scholar 

  7. Ganai SA (2016) Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharmaceutical Biol 54:1926–1935

    CAS  Article  Google Scholar 

  8. Ganai SA, Abdullah E, Rashid R, Altaf M (2017) Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders. Frontiers in molecular neuroscience 10, 357

  9. Ganai SA, Farooq Z, Banday S, Altaf M (2018) silico approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms. Future Med Chem 10:1925–1945

    CAS  Article  Google Scholar 

  10. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E (2019) Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv 3:508–518

    CAS  Article  Google Scholar 

  11. Gryder BE, Sodji QH, Oyelere AK (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4:505–524

    CAS  Article  Google Scholar 

  12. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of medicinal chemistry 47:1750–1759

    CAS  Article  Google Scholar 

  13. Ho TCS, Chan AHY, Ganesan A (2020) Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. Journal of medicinal chemistry

  14. Kalyaanamoorthy S, Chen Y-PP (2013) Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1834, 317–328

  15. Liu Y, Grimm M, Dai W-t, Hou M-c, Xiao Z-X, Cao Y (2020) CB-Dock: a web server for cavity detection-guided protein–ligand blind docking. Acta Pharmacol Sin 41:138–144

    CAS  Article  Google Scholar 

  16. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234

    CAS  Article  Google Scholar 

  17. Meng X-Y, Zhang H-X, Mezei M, Cui M (2011) Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 7:146–157

    CAS  Article  Google Scholar 

  18. Noureen N, Rashid H, Kalsoom S (2010) Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 66:625–633

    CAS  Article  Google Scholar 

  19. Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC, Hentze H, Pasha MK, Jayaraman R, Ethirajulu K, Wood JM (2012) The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2:e69–e69

    CAS  Article  Google Scholar 

  20. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9:642–652

    CAS  Article  Google Scholar 

  21. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612

    CAS  Article  Google Scholar 

  22. Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49:2356–2368

    CAS  Article  Google Scholar 

  23. Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein-ligand interaction profiler. Nucleic acids research 43, W443-W447

  24. Sanaei M, Kavoosi F (2019) Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers. Adv Biomed Res 8:63–63

    CAS  Article  Google Scholar 

  25. Shankaran KS, Ganai SA, K PA, Mahadevan PB, V (2017) In silico and In vitro evaluation of the anti-inflammatory potential of Centratherum punctatum Cass-A. J Biomol Struct Dyn 35:765–780

    CAS  Article  Google Scholar 

  26. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Tu B, Zhang M, Liu T, Huang Y (2020) Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Front Cell Developmental Biol 8

  28. Wang H, Yu N, Chen D, Lee KCL, Lye PL, Chang JWW, Deng W, Ng MCY, Lu T, Khoo ML, Poulsen A, Sangthongpitag K, Wu X, Hu C, Goh KC, Wang X, Fang L, Goh KL, Khng HH, Goh SK, Yeo P, Liu X, Bonday Z, Wood JM, Dymock BW, Kantharaj E, Sun ET (2011) Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. J Med Chem 54, 4694–4720

Download references


Ganai SA acknowledges monetary support from Science and Engineering Research Board. The author used the power facility of SDAU palanpur for writing this manuscript.

Author information



Corresponding author

Correspondence to Shabir Ahmad Ganai.

Ethics declarations

Conflict of interest


Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ganai, S.A. Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy. In Silico Pharmacol. 9, 18 (2021).

Download citation


  • Pracinostat
  • HDAC1-3
  • HDAC8
  • XP-molecular docking
  • CB-Dock
  • e-Pharmacophores method